Schizophrenia. Schizophrenia, unspecified
Conditions
Interventions
Intervention 1: Intervention group: Patients who receive memantine in addition to standard schizophrenia treatment. The dose of the drug starts at 5 mg daily and increases by 5 mg every week until it
Sponsors
Zahedan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Diagnosis of schizophrenia by a physician according to the DSM-5 criteria. Informed consent obtained from the patient or their legal guardian for participation in the study
Exclusion criteria
Exclusion criteria: Pregnancy or breastfeeding for female patients. History of allergy to memantine History of liver or kidney disorders History of cardiac conduction disorders or arrhythmias
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Psychotic symptom status. Timepoint: Day zero (before the start of the intervention) and eight weeks after the intervention. Method of measurement: Cognitive impairment questionnaire.;Cognitive symptoms. Timepoint: Day zero (before the start of the intervention) and eight weeks after the intervention. Method of measurement: Cognitive impairment questionnaire.;Negative symptoms. Timepoint: Day zero (before the start of the intervention) and eight weeks after the intervention. Method of measurement: Cognitive impairment questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAzadeh Hasanzehi
Zahedan University of Medical Sciences
Outcome results
None listed